潘多姆檢測(德國PanTum Detect)是通過檢測巨噬細胞吞噬的全身腫瘤共有標誌物 Apo10 和 TKTL1,來判斷全身腫瘤組織病變的檢測技術。
基本介紹
- 中文名:潘多姆檢測
- 外文名:PanTum Detect
- 所屬分類:腫瘤預防篩查檢測方法
簡介,技術創新,檢測試驗流程,判讀標準,檢測報告,臨床套用,相關臨床研究,認證及相關資質,腫瘤預防中套用,
簡介
技術創新
潘多姆檢測有兩大顛覆性技術創新:
- 首次發現全身腫瘤共有腫瘤標誌物Apo10和TKTL1
- Apo10是DNaseX的一段抗原表位,DNaseX在細胞凋亡過程中起關鍵作用
Apo10在細胞中累積,預示細胞凋亡受阻,細胞凋亡受阻是腫瘤組織病變的開端
Apo10檢測值增高預示腫瘤/增殖性疾病的形成
- TKTL1主要調節糖酵解代謝途徑,在惡性腫瘤細胞中高表達與腫瘤的侵襲性、治療抗性及預後等有密切關係。
TKTL1使腫瘤細胞通過糖酵解方式迅速代謝葡萄糖,產生能量並排出大量乳酸
TKTL1高表達,為腫瘤提供酸性環境,對抗免疫殺傷並增強腫瘤侵襲性
TKTL1促進核糖核苷合成並加速DNA複製,提高腫瘤細胞的治療抗性
2. 首創基於巨噬細胞的檢測實驗體系 —— EDIM 檢測實驗體系
① 巨噬細胞能夠主動到達全身所有病變組織,因此一次檢測即可覆蓋全身所有腫瘤。
② 巨噬細胞在腫瘤形成、發展各個階段(癌前病變、原位癌、早期癌)均能主動的吞噬、富集樣本,從而徹底解決了早期病變樣本難以富集的難題。
③ 巨噬細胞具有極高靈敏度。
檢測試驗流程
基於流式檢測平台人工智慧判讀的檢測流程
判讀標準
檢測報告
臨床套用
在潘多姆檢測達到陽性(AP-T≥260且Apo10≥140)時即視為腫瘤告警,有必要進行全身PET-CT檢查,及時溯源定位。
相關臨床研究
1. 國內回顧性臨床研究
中山大學腫瘤醫院於2023年6月13日在歐洲《細胞腫瘤學》雜誌發表研究成果,結論:APT在鑑別早期肺癌(原位癌和 I 期癌,占比81%)和肺結節及健康人群中,AUROC=0.9132
文獻索引:Apo10 and TKTL1 in blood macrophages as biomarkers for differentiating lung cancer from benign lung lesions: a comparative study with conventional biomarkers. Xie, Chuanbo et al. Cell Oncol. (Dordrecht) 10.1007/s13402-023-00838-1. 2023.
2. 國際前瞻性臨床研究
2022年5月20日發表於歐洲《臨床與醫學影像雜誌》
關鍵字:普通人群50-70歲;Apo10+TKTL1 ≥ 260 且 Apo10≥140 時進行 PET-CT;
文獻索引:Blood-test based targeted visualization enables early detection of premalignant and malignant tumors in asymptomatic individuals. Burg S, et al. J Clin Med Images (2022) 6(9).
3.其他已發表國際臨床研究文獻
序號 | 文獻名稱 |
1 | Apo10 and TKTL1 in blood macrophages as biomarkers for differentiating lung cancer from benign lung lesions: a comparative study with conventional biomarkers. Xie, Chuanbo et al. Cell Oncol. (Dordrecht) 10.1007/s13402-023-00838-1. 2023. |
2 | Blood-test based targeted visualization enables early detection of premalignant and malignant tumors in asymptomatic individuals. Burg S, et al. J Clin Med Images (2022) 6(9). |
3 | Biomarkers Apo10 and TKTL1: Epitope-detection in monocytes (EDIM) as a ew diagnostic approach for cholangiocellular, pancreatic and colorectal carcinoma, S. Saman Cancer Biomarkers 27 (2020) 129–137 |
4 | APC/CCDH1 synchronizes ribose-5-phosphate levels and DNA synthesis to cell cycle progression, Yang Li et al. Nat Commun. 2017, 10, 2502 |
5 | EDIM-TKTL1/Apo10 Blood Test: An InnAP-Te Immune System Based Liquid Biopsy for the Early Detection, Characterization and Targeted Treatment of Cancer Johannes F. Coy Int. J. Mol. Sci. 2017, 18, 878 |
6 | Analysis of circulating CD14D/CD16Dmonocyte-derived macrophages (MDMs) in the peripheral blood of patients with oral squamous cell carcinoma Martin Grimm et al. ORAL AND MAXILLOFACIAL PATH. 2016,03 |
7 | A biomarker based detection and characterization of carcinomas exploiting two fundamental biophysical mechanisms in mammalian cells Martin Grimm et al. BMC Cancer 2013, 13:569 |
8 | Diagnostic use of epitope detection in monocytes blood test for early detection of colon cancer metastasis Natalie Jansen, Johannes F. Coy Future Oncol. (2013) 9(4), 605–609 |
9 | EDIM-TKTL1 blood test: a noninvasive method to detect upregulated glucose metabolism in patients with malignancies Oliver Feyen et al. Future Oncol. (2012) 8(10), 1349–1359 |
10 | Lack of transketolase-like (TKTL) 1 aggravates murine experimental colitis Susanne Bentz et al. Am J Physiol Gastrointest Liver Physiol 300: G598–G607, 2011 |
11 | Transketolase-like protein 1 (TKTL1) is required for rapid cell growth and full viability of human tumor cells Xiaojun Xu et al. Int. J. Cancer: 124, 1330–1337, 2009 |
12 | Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted S. Langbein et al. British Journal of Cancer 94, 578 – 585, 2006 |
認證及相關資質
經海南省藥監局批准,正式進入海南博鰲醫療先行示範區
腫瘤預防中套用
潘多姆檢測技術可以更容易的識別癌前腫瘤或惡性腫瘤的風險,通過AP-T和Apo10數值來量化全身斷全⾝腫瘤組織病變。
當潘多姆檢測AP-T數值大於等於260且Apo10數值大於等於140時,預示著惡性腫瘤可能性較高,臨床上多為原位癌或早期癌階段。當AP-T數值大於等於260且Apo10數值小於140或AP-T小於260時,數值越高臨床上預示組織病變程度越高,當AP-T越接近260時,不能完全排除少部分原位癌、早期癌。當AP-T數值小於240時,預示著存在惡性腫瘤的可能性較低。